Revolution Medicines: A Rising Star in Cancer Research

Company Overview

• Valuation: $15 billion
• Focus: Developing treatments for cancers caused by mutations in RAS proteins
• Challenge: These cancers are notoriously difficult to treat

Stock Performance

• Yearly Increase: Nearly 60%
• All-Time High: $79.07 (December 3rd)
• Revenue Growth (Next Year): 903.48%
• Earnings Projection (Next Year): Decrease by 12.15%

Analyst Sentiment

• Wall Street Opinions:
• 19 "Strong Buys"
• 2 "Moderate Buys"
• 1 "Hold"
• Other Platforms:
• CFRA’s MarketScope Advisor: "Strong Sell"
• Morningstar: Undervalued with a price target of $81.52

Investor Sentiment

• Mixed Reactions: Wall Street is bullish, but individual investors are cautious
• Short Interest: 9.85% of the float

Key Considerations

• Clinical Stage: Heavy investment in research
• Future Profits: Dependent on FDA approval
• Risk Level: Highly speculative